Company: ARMP
Filing Date: 2025-10-22
Form Type: 8-K
Source: 0001104659-25-101447
Chunk: 0

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-10-22
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01      Regulation FD Disclosure.  

On October 22, 2025, Armata Pharmaceuticals, Inc. (the “ Company”)
issued a press release announcing the presentation of positive results from its recently completed Phase 2a diSArm study of AP-SA02 as
a potential treatment for complicated Staphylococcus aureusbacteremia at IDWeek 2025TM. The full text of the press
release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.